|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 June 2002, Vol. 99, No. 11, pp. 3916-3922
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Infusion of cytomegalovirus (CMV)-specific T cells for the
treatment of CMV infection not responding to antiviral chemotherapy
Hermann Einsele,
Eddy Roosnek,
Nathalie Rufer,
Christian Sinzger,
Susanne Riegler,
Jürgen Löffler,
Ulrich Grigoleit,
Arnaud Moris,
Hans-Georg Rammensee,
Lothar Kanz,
Annette Kleihauer,
Friederike Frank,
Gerhard Jahn, and
Holger Hebart
From the Medizinische Klinik und Poliklinik, Abteilung
II, Tübingen, Germany; Division of Immunology and Allergology,
University of Geneva, Switzerland; National Center for Competence and
Research Molecular Oncology, Swiss Institut for Experimental Cancer
Research, Epalinges, Switzerland; Abteilung Medizinische Virologie und
Epidemiologie der Viruskrankheiten, Tübingen, Germany; and
Institut für Zellbiologie Universität Tübingen,
Germany.
We adoptively transferred donor-derived cytomegalovirus
(CMV)-specific T-cell lines into 8 stem cell transplant recipients lacking CMV-specific T-cell proliferation. All patients, of whom one
was infected by a CMV strain that was genotypically ganciclovir resistant, had received unsuccessful antiviral chemotherapy for more
than 4 weeks. CMV-specific lines had been prepared by repetitive stimulation with CMV antigen, which increased the percentage of CMV-specific T cells and ablated alloreactivity completely even against
patients mismatched for 1 to 3 HLA antigens. After transfer of
107 T cells/m2 at a median of 120 days (range,
79-479 days) after transplantation, no side effects were noticed.
Despite cessation of antiviral chemotherapy, the CMV load dropped
significantly in all 7 evaluable patients, with a maximal reduction
after a median of 20 days (range, 5-31 days). In 2 patients with high
virus load, the antiviral effect was only transient. One of these
patients received a second T-cell infusion, which cleared the virus
completely. At a median of 11 days after transfer, CMV-specific T-cell
proliferation was demonstrated in 6 patients, and an increase in
CMV-specific CD4+ T cells was demonstrated in 5 patients.
In 6 patients, 1.12 to 41 CMV-specific CD8+ T cells/µL
blood were detected at a median of 13 days after transfer, with an
increase in all patients lacking CMV-specific CD8+ T cells
prior to transfer. Hence, anti-CMV cellular therapy was successful in 5 of 7 patients, whereas in 2 of 7 patients, who received an intensified
immune suppression at the time of or after T-cell therapy, only
transient reductions in virus load were obtained.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. Zhou, J. Longmate, S. F. Lacey, J. M. Palmer, G. Gallez-Hawkins, L. Thao, R. Spielberger, R. Nakamura, S. J. Forman, J. A. Zaia, et al.
Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients
Blood,
June 18, 2009;
113(25):
6465 - 6476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Boeckh and P. Ljungman
How we treat cytomegalovirus in hematopoietic cell transplant recipients
Blood,
June 4, 2009;
113(23):
5711 - 5719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. McAulay, T. Haque, G. Urquhart, C. Bellamy, D. Guiretti, and D. H. Crawford
Epitope Specificity and Clonality of EBV-Specific CTLs Used to Treat Posttransplant Lymphoproliferative Disease
J. Immunol.,
March 15, 2009;
182(6):
3892 - 3901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. van Loenen, R. S. Hagedoorn, M. G.D. Kester, M. Hoogeboom, R. Willemze, J.H. F. Falkenburg, and M. H.M. Heemskerk
Kinetic Preservation of Dual Specificity of Coprogrammed Minor Histocompatibility Antigen-Reactive Virus-Specific T Cells
Cancer Res.,
March 1, 2009;
69(5):
2034 - 2041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Crough and R. Khanna
Immunobiology of Human Cytomegalovirus: from Bench to Bedside
Clin. Microbiol. Rev.,
January 1, 2009;
22(1):
76 - 98.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Joshi, J. Tang, M. Kuzma, J. Wagner, B. Mookerjee, J. Filicko, M. Carabasi, N. Flomenberg, and P. Flomenberg
Adenovirus DNA polymerase is recognized by human CD8+ T cells
J. Gen. Virol.,
January 1, 2009;
90(1):
84 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schroer and T. Shenk
Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus
PNAS,
December 9, 2008;
105(49):
19468 - 19473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. P. Micklethwaite, L. Clancy, U. Sandher, A. M. Hansen, E. Blyth, V. Antonenas, M. M. Sartor, K. F. Bradstock, and D. J. Gottlieb
Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation
Blood,
November 15, 2008;
112(10):
3974 - 3981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baron and J.-L. Davignon
Inhibition of IFN-{gamma}-Induced STAT1 Tyrosine Phosphorylation by Human CMV Is Mediated by SHP2
J. Immunol.,
October 15, 2008;
181(8):
5530 - 5536.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Hossain, J. D. Roback, F. Wang, and E. K. Waller
Host and Donor Immune Responses Contribute to Antiviral Effects of Amotosalen-Treated Donor Lymphocytes following Early Posttransplant Cytomegalovirus Infection
J. Immunol.,
May 15, 2008;
180(10):
6892 - 6902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jorritsma, A. D. Bins, T. N.M. Schumacher, and J. B.A.G. Haanen
Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer
Cancer Res.,
April 1, 2008;
68(7):
2455 - 2462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Klenovsek, F. Weisel, A. Schneider, U. Appelt, S. Jonjic, M. Messerle, B. Bradel-Tretheway, T. H. Winkler, and M. Mach
Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells
Blood,
November 1, 2007;
110(9):
3472 - 3479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Delmas, P. Brousset, D. Clement, E. Le Roy, and J.-L. Davignon
Anti-IE1 CD4+ T-cell clones kill peptide-pulsed, but not human cytomegalovirus-infected, target cells
J. Gen. Virol.,
September 1, 2007;
88(9):
2441 - 2449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. R. Humphreys, A. Loewendorf, C. de Trez, K. Schneider, C. A. Benedict, M. W. Munks, C. F. Ware, and M. Croft
OX40 Costimulation Promotes Persistence of Cytomegalovirus-Specific CD8 T Cells: A CD4-Dependent Mechanism
J. Immunol.,
August 15, 2007;
179(4):
2195 - 2202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Biagi, V. Marin, G. M. P. Giordano Attianese, E. Dander, G. D'Amico, and A. Biondi
Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies
Haematologica,
March 1, 2007;
92(3):
381 - 388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. C. Wehler, M. Nonn, B. Brandt, C. M. Britten, M. Grone, M. Todorova, I. Link, S. A. Khan, R. G. Meyer, C. Huber, et al.
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines
Blood,
January 1, 2007;
109(1):
365 - 373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Meyer, C. M. Britten, D. Wehler, K. Bender, G. Hess, A. Konur, U. F. Hartwig, T. C. Wehler, A. J. Ullmann, C. Gentilini, et al.
Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation
Blood,
January 1, 2007;
109(1):
374 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Casazza, M. R. Betts, D. A. Price, M. L. Precopio, L. E. Ruff, J. M. Brenchley, B. J. Hill, M. Roederer, D. C. Douek, and R. A. Koup
Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation
J. Exp. Med.,
December 25, 2006;
203(13):
2865 - 2877.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Heemskerk, T. van Vreeswijk, L. A. Veltrop-Duits, C. C. Sombroek, K. Franken, R. M. Verhoosel, P. S. Hiemstra, D. van Leeuwen, M. E. Ressing, R. E. M. Toes, et al.
Adenovirus-Specific CD4+ T Cell Clones Recognizing Endogenous Antigen Inhibit Viral Replication In Vitro through Cognate Interaction
J. Immunol.,
December 15, 2006;
177(12):
8851 - 8859.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kausche, T. Wehler, E. Schnurer, V. Lennerz, W. Brenner, S. Melchior, M. Grone, M. Nonn, S. Strand, R. Meyer, et al.
Superior Antitumor In vitro Responses of Allogeneic Matched Sibling Compared with Autologous Patient CD8+ T Cells
Cancer Res.,
December 1, 2006;
66(23):
11447 - 11454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Haveman, M. Bierings, E. Legger, M. R. Klein, W. de Jager, H. G. Otten, S. Albani, W. Kuis, A. Sette, and B. J. Prakken
Novel pan-DR-binding T cell epitopes of adenovirus induce pro-inflammatory cytokines and chemokines in healthy donors
Int. Immunol.,
November 1, 2006;
18(11):
1521 - 1529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Beck, M. S. Topp, U. Koehl, E. Roilides, M. Simitsopoulou, M. Hanisch, J. Sarfati, J. P. Latge, T. Klingebiel, H. Einsele, et al.
Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus
Blood,
March 15, 2006;
107(6):
2562 - 2569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. M. Wang, G. Y. Zhang, Y. Wang, M. Hu, H. Wu, D. Watson, S. Hori, I. E. Alexander, D. C.H. Harris, and S. I. Alexander
Foxp3-Transduced Polyclonal Regulatory T Cells Protect against Chronic Renal Injury from Adriamycin
J. Am. Soc. Nephrol.,
March 1, 2006;
17(3):
697 - 706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. A. Shlobin, E. E. West, N. Lechtzin, S. M. Miller, M. Borja, J. B. Orens, L. K. Dropulic, and J. F. McDyer
Persistent Cytomegalovirus-Specific Memory Responses in the Lung Allograft and Blood following Primary Infection in Lung Transplant Recipients
J. Immunol.,
February 15, 2006;
176(4):
2625 - 2634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Roback
Vaccine-Enhanced Donor Lymphocyte Infusion (veDLI)
Hematology,
January 1, 2006;
2006(1):
486 - 491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Chalandon, S. Degermann, J. Villard, L. Arlettaz, L. Kaiser, S. Vischer, S. Walter, M. H. M. Heemskerk, R. A. W. van Lier, C. Helg, et al.
Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications
Blood,
January 1, 2006;
107(1):
389 - 396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Einsele
T-cell therapy for viral and fungal infections
Blood,
December 15, 2005;
106(13):
4023 - 4023.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Perruccio, A. Tosti, E. Burchielli, F. Topini, L. Ruggeri, A. Carotti, M. Capanni, E. Urbani, A. Mancusi, F. Aversa, et al.
Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation
Blood,
December 15, 2005;
106(13):
4397 - 4406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Delmas, L. Martin, M. Baron, J. A. Nelson, D. N. Streblow, and J.-L. Davignon
Optimization of CD4+ T Lymphocyte Response to Human Cytomegalovirus Nuclear IE1 Protein through Modifications of Both Size and Cellular Localization
J. Immunol.,
November 15, 2005;
175(10):
6812 - 6819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Lang, M. Recher, A. A. Navarini, S. Freigang, N. L. Harris, M. van den Broek, B. Odermatt, H. Hengartner, and R. M. Zinkernagel
Requirement for Neutralizing Antibodies to Control Bone Marrow Transplantation-Associated Persistent Viral Infection and to Reduce Immunopathology
J. Immunol.,
October 15, 2005;
175(8):
5524 - 5531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Sylwester, B. L. Mitchell, J. B. Edgar, C. Taormina, C. Pelte, F. Ruchti, P. R. Sleath, K. H. Grabstein, N. A. Hosken, F. Kern, et al.
Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects
J. Exp. Med.,
September 6, 2005;
202(5):
673 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cobbold, N. Khan, B. Pourgheysari, S. Tauro, D. McDonald, H. Osman, M. Assenmacher, L. Billingham, C. Steward, C. Crawley, et al.
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers
J. Exp. Med.,
August 1, 2005;
202(3):
379 - 386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Chen, Q. Wang, J. Cui, W. Yang, Q. Shi, Z. Hua, J. Ji, and P. Shen
Induction of Apoptosis in Mouse Liver by Microcystin-LR: A Combined Transcriptomic, Proteomic, And Simulation Strategy
Mol. Cell. Proteomics,
July 1, 2005;
4(7):
958 - 974.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Roth, G. M. Baerlocher, M. Schertzer, E. Chavez, U. Duhrsen, and P. M. Lansdorp
Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT
Blood,
July 1, 2005;
106(1):
43 - 50.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Trivedi, R. Y. Williams, R. J. O'Reilly, and G. Koehne
Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy
Blood,
April 1, 2005;
105(7):
2793 - 2801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Manley, L. Luy, T. Jones, M. Boeckh, H. Mutimer, and S. R. Riddell
Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection
Blood,
August 15, 2004;
104(4):
1075 - 1082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Wang, C. La Rosa, S. Mekhoubad, S. F. Lacey, M. C. Villacres, S. Markel, J. Longmate, J. D. I. Ellenhorn, R. F. Siliciano, C. Buck, et al.
Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells
Blood,
August 1, 2004;
104(3):
847 - 856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Li Pira, L. Bottone, F. Ivaldi, R. Pelizzoli, F. Del Galdo, L. Lozzi, L. Bracci, A. Loregian, G. Palu, R. De Palma, et al.
Identification of new Th peptides from the cytomegalovirus protein pp65 to design a peptide library for generation of CD4 T cell lines for cellular immunoreconstitution
Int. Immunol.,
May 1, 2004;
16(5):
635 - 642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Rauser, H. Einsele, C. Sinzger, D. Wernet, G. Kuntz, M. Assenmacher, J. D. M. Campbell, and M. S. Topp
Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants
Blood,
May 1, 2004;
103(9):
3565 - 3572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. V. Verra, A. Jorritsma, K. Weijer, J. J. Ruizendaal, A. Voordouw, P. Weder, E. Hooijberg, T. N. M. Schumacher, J. B. A. G. Haanen, H. Spits, et al.
Human Telomerase Reverse Transcriptase-Transduced Human Cytotoxic T Cells Suppress the Growth of Human Melanoma in Immunodeficient Mice
Cancer Res.,
March 15, 2004;
64(6):
2153 - 2161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Boeckh and W. G. Nichols
The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy
Blood,
March 15, 2004;
103(6):
2003 - 2008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kondo, Y. Akatsuka, K. Kuzushima, K. Tsujimura, S. Asakura, K. Tajima, Y. Kagami, Y. Kodera, M. Tanimoto, Y. Morishima, et al.
Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles
Blood,
January 15, 2004;
103(2):
630 - 638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Roback, M. S. Hossain, L. Lezhava, J. W. Gorechlad, S. A. Alexander, D. L. Jaye, S. Mittelstaedt, S. Talib, J. E. Hearst, C. D. Hillyer, et al.
Allogeneic T Cells Treated with Amotosalen Prevent Lethal Cytomegalovirus Disease without Producing Graft-versus-Host Disease Following Bone Marrow Transplantation
J. Immunol.,
December 1, 2003;
171(11):
6023 - 6031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Meijer, G. J. Boland, and L. F. Verdonck
Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants
Clin. Microbiol. Rev.,
October 1, 2003;
16(4):
647 - 657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Papanicolaou, J.-B. Latouche, C. Tan, J. Dupont, J. Stiles, E. G. Pamer, and M. Sadelain
Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele
Blood,
October 1, 2003;
102(7):
2498 - 2505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Heemskerk, L. A. Veltrop-Duits, T. van Vreeswijk, M. M. ten Dam, S. Heidt, R. E. M. Toes, M. J. D. van Tol, and M. W. Schilham
Extensive Cross-Reactivity of CD4+ Adenovirus-Specific T Cells: Implications for Immunotherapy and Gene Therapy
J. Virol.,
June 1, 2003;
77(11):
6562 - 6566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kaur, N. Kassis, C. L. Hale, M. Simon, M. Elliott, A. Gomez-Yafal, J. D. Lifson, R. C. Desrosiers, F. Wang, P. Barry, et al.
Direct Relationship between Suppression of Virus-Specific Immunity and Emergence of Cytomegalovirus Disease in Simian AIDS
J. Virol.,
May 15, 2003;
77(10):
5749 - 5758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. La Rosa, Z. Wang, J. C. Brewer, S. F. Lacey, M. C. Villacres, R. Sharan, R. Krishnan, M. Crooks, S. Markel, R. Maas, et al.
Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice
Blood,
November 15, 2002;
100(10):
3681 - 3689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
